Research ArticleArticle
Knee Pain and a Prior Injury Are Associated with Increased Risk of a New Knee Injury: Data from the Osteoarthritis Initiative
Jeffrey B. Driban, Grace H. Lo, Charles B. Eaton, Lori Lyn Price, Bing Lu and Timothy E. McAlindon
The Journal of Rheumatology June 2015, jrheum.150016; DOI: https://doi.org/10.3899/jrheum.150016
Jeffrey B. Driban
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Grace H. Lo
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Charles B. Eaton
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Lori Lyn Price
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Bing Lu
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Timothy E. McAlindon
From the Division of Rheumatology, and The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Tufts Clinical and Translational Science Institute, Tufts University; Brigham and Women’s Hospital; Harvard Medical School, Boston, Massachusetts; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center; Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, Texas; Center for Primary Care and Prevention, Alpert Medical School of Brown University, Providence, Rhode Island, USA. Analyses supported by grants from the US National Institutes of Health (NIH; Eaton: 268201000020C-1-0-1 and Driban: 1R01AR065977-01A1). The Osteoarthritis Initiative (OAI) is a public-private partnership consisting of 5 contracts (N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261, N01-AR-2-2262) funded by the NIH, a branch of the US Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corporation, GlaxoSmithKline, and Pfizer Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. Also supported in part with resources at the Veterans Affairs (VA) HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413) at the Michael E. DeBakey VA Medical Center, Houston, Texas, USA. J.B. Driban, PhD, ATC, CSCS, Assistant Professor, Division of Rheumatology, Tufts Medical Center; G.H. Lo, MD, MSc, Assistant Professor, Medical Care Line and Research Care Line, HSR&D Center of Excellence, Michael E. DeBakey VA Medical Center, and Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine; C.B. Eaton, MD, MS, Director of Primary Care and Prevention, Center for Primary Care and Prevention, Alpert Medical School of Brown University; L.L. Price, MAS, Statistician, Instructor, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and Tufts Clinical and Translational Science Institute, Tufts University; B. Lu, MD, DrPH, Assistant Professor, Brigham and Women’s Hospital, and Harvard Medical School; T.E. McAlindon, MD, MPH, Chief of Division of Rheumatology, Division of Rheumatology, Tufts Medical Center. Address correspondence to Dr. J. Driban, Division of Rheumatology, Tufts Medical Center, 800 Washington St., Box 406, Boston, Massachusetts 02111, USA. E-mail: jeffrey.driban@tufts.edu. Accepted for publication April 20, 2015.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Knee Pain and a Prior Injury Are Associated with Increased Risk of a New Knee Injury: Data from the Osteoarthritis Initiative
Jeffrey B. Driban, Grace H. Lo, Charles B. Eaton, Lori Lyn Price, Bing Lu, Timothy E. McAlindon
The Journal of Rheumatology Jun 2015, jrheum.150016; DOI: 10.3899/jrheum.150016
Knee Pain and a Prior Injury Are Associated with Increased Risk of a New Knee Injury: Data from the Osteoarthritis Initiative
Jeffrey B. Driban, Grace H. Lo, Charles B. Eaton, Lori Lyn Price, Bing Lu, Timothy E. McAlindon
The Journal of Rheumatology Jun 2015, jrheum.150016; DOI: 10.3899/jrheum.150016